RNS Number : 4907X
Immupharma PLC
24 November 2017
 


24 NOVEMBER 2017

 

 

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

Grant of Options

 

 

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces the approval of the grant of options over a total of 7,875,000 ordinary shares of 10p each in the Company ("Ordinary Shares") to certain of its Directors, non-executive Directors, employees and consultants representing 5.26% of ImmuPharma's Ordinary Shares and total voting rights on a fully diluted basis (the "Options"). 

 

The exercise price for the Options is 98.62 pence being the closing middle market share price on 23 November 2017.  The Options will vest subject to certain conditions after three years and are exercisable between three and ten years from the date of grant.

 

Options granted to Executive Directors and employees

 

Upon the recommendation of the Company's remuneration committee, the Company has granted 4,875,000 of the Options to the Company's Executive Directors and certain other employees pursuant to the Company's Share Option Plan which was adopted on 30 March 2017 (the "2017 Plan").  The amount of Options granted on 24 November 2017 to the Executive Directors is summarised in the following table:

 

Director

Ordinary Shares under Option

Dimitri Dimitriou

1,500,000

Robert Zimmer

1,875,000*

*includes 375,000 Options granted to Elisabeth Zimmer, Robert Zimmer's wife, who is also an employee of the Company.

 

Messrs Dimitriou and Zimmer currently have the following interests in issued Ordinary Shares:

 

Director

Number of Ordinary Shares

% of issued share capital at 24 November 2017

Dimitri Dimitriou

3,567,430

2.69

Robert Zimmer

25,344,514*

19.12

*includes 792,961 shares held by Elisabeth Zimmer, Robert Zimmer's wife, who is also an employee of the Company.

 

Following the grant of the options referred to above, Messrs Dimitriou and Zimmer will have the following interests in share options in the Company:

 

Director

Number of options

Exercise Price

Expiry Date

Dimitri Dimitriou

140,000

1,000,000

1,500,000

86.50p

50.25p

98.62p

04.02.2019

30.03.2027

24.11.2027

Robert Zimmer

200,000*

50,000*

100,000*

1,250,000*

1,875,000*

86.50p

90.75p

43.88p

50.25p

98.62p

04.02.2019

24.11.2021

02.06.2026

30.03.2027

24.11.2027

*includes options granted to Elisabeth Zimmer, Robert Zimmer's wife, who is also an employee of the Company

 

Following this grant of Options summarised above, the total number of share options outstanding pursuant to the 2017 Plan will be 8,125,000 representing 6.15% of ImmuPharma's Ordinary Shares and total voting rights on a fully diluted basis.  2,005,000 Options remain outstanding pursuant to the Company's previous share option plan.  Together, there are 10,130,000 Options outstanding representing 7.64% of ImmuPharma's Ordinary Shares and total voting rights on a fully diluted basis.

 

Options granted to Non-executive Directors

 

The Company has also granted certain Options to Non-executive Directors as summarised in the following table:

 

Director

Ordinary Shares under Option

Tim McCarthy

1,500,000

Franco di Muzio

300,000

Stephane Mery

300,000

 

Messrs McCarthy, di Muzio and Mery currently have the following interests in issued Ordinary Shares:

 

Director

Number of Ordinary Shares

% of issued share capital at 23 November 2017

Tim McCarthy

38,462

0.03%

Franco di Muzio

99,412

0.08%

Stephane Mery

21,490

0.02%

 

Following the grant of the Options referred to above, Messrs McCarthy, di Muzio and Mery will have the following interests in options over the Company's Ordinary Shares:

 

Director

Number of Ordinary Shares under Option

Exercise Price

Expiry Date

Tim McCarthy

500,000

1,000,000

1,500,000

43.88p

56.75p

98.62p

02.06.2026

12.07.2027

24.11.2027

Franco di Muzio

100,000

100,000

200,000

300,000

86.50p

43.88p

56.75p

98.62p

04.02.2019

02.06.2026

12.07.2027

24.11.2027

Stephane Mery

100,000

200,000

300,000

43.88p

56.75p

98.62p

02.06.2026

12.07.2027

24.11.2027

 

Total Share Options

As stated above, the total options outstanding under both the 2017 Plan and the Company's previous share option plan is 10,130,000, representing 7.64% of ImmuPharma's Ordinary Shares and total voting rights on a fully diluted basis.  The total options outstanding that have been granted to non-employees and consultants is 5,185,000.  The total warrants outstanding is 153,850.  Taken altogether, there are currently 15,468,850 outstanding options and warrants, representing 11.67% of ImmuPharma's Ordinary Shares and total voting rights on a fully diluted basis.

 

This announcement contains inside information for the purpose of Article 7 of Regulation (EU) 596/2014.

 

Ends

 

For further information, please contact:

 

ImmuPharma plc (www.immupharma.co.uk)


Tim McCarthy, Chairman

Lisa Baderoon, Head of Investor Relations

Twitter: @immupharma

 

+44 (0) 20 7152 4080

+44 (0) 7721 413496

Northland Capital Partners Limited (NOMAD & Broker)

Patrick Claridge, Corporate Finance

David Hignell, Corporate Finance

Jamie Spotswood, Corporate Finance

Rob Rees, Corporate Broking

+44 (0) 20 3861 6625

 

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IOEBIBTTMBATBIR ]]>